Table 3. Clinical and cost outcome variables.
| Variable | Group I | Group II | Group III | P value |
|---|---|---|---|---|
| LOS (days) | 9.5 | 9.5 | 8.3 | 0.966 |
| EBL (mL) | 215 | 221 | 250 | 0.845 |
| Blood transfusion (units PRBC) | 1.93 | 0.94 | 1 | 0.398 |
| Disease status at follow-up | <0.001 | |||
| Alive with disease | 3 (20%) | 25 (83%) | 3 (50%) | |
| Dead of disease | 11 (73%) | 5 (17%) | 2 (33%) | |
| Dead of complications | 1 (7%) | 0 (0%) | 1 (17%) | |
| Direct cost (USD) | 18,836.53 | 16,093.57 | 17,171.93 | 0.758 |
| Total cost (USD) | 31,997.24 | 27,357.16 | 29,668.59 | 0.778 |
Disease status at follow-up: 3 patients in Group II and 1 patient in Group III had inadequate records to evaluate. LOS, length of stay; EBL, estimated blood loss; PRBC, packed red blood cells; USD, United States dollars.